welcome
CNBC

CNBC

Health

Health

Moderna beats on revenue but loses more than expected as it scales down manufacturing

CNBC
Summary
Nutrition label

87% Informative

Moderna beat on fourth-quarter revenue but lost more than expected for the period.

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the rapid decline of its Covid vaccine.

Moderna reiterated its full-year 2025 product sales guidance of $1.5 billion to $2.5billion .

Cost of sales for the fourth quarter was $739 million , down 20% from the same period a year ago .

Research and development expenses dropped by 20% to $1.1 billion .

Moderna expects a decision from the FDA on the next-generation Covid shot in May , and a potential expanded approval for RSV in June .

VR Score

93

Informative language

95

Neutral language

87

Article tone

formal

Language

English

Language complexity

48

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

Source diversity

1

Affiliate links

no affiliate links